Biotransformation and Disposition of Ketamine

  title={Biotransformation and Disposition of Ketamine},
  author={Tsun Chang and Anthony J. Glazko},
  journal={International Anesthesiology Clinics},
The binding of ketamine to plasma proteins: Emphasis on human plasma
It was shown that binding of K to plasma and albumin is dependent on pH; binding is decreased at pH lower than 7.4 and increased at higher pH; the partition coefficient between an organic phase and buffer was found to be sensitive to small pH changes. Expand
Assessment of a medetomidine/propofol total intravenous anaesthesia (TIVA) for clinical anaesthesia in equidae.
Medetomidine/propofol TIVA at the dose rates studied produced good quality anaesthesia with cardiopulmonary depression within ranges commonly recorded during inhalation anaesthesia in horses, and appeared inferior to that achieved with induction techniques which included ketamine. Expand
Pharmacokinetics of Intravenous Anaesthetics: Implications for Clinical Use
SummaryIntravenous anaesthetics comprise a variety of drugs that differ in chemical structure but share a suitable combination of physical properties that confer ready penetration of the blood-brainExpand
Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications
Preclinical studies indicate that hydroxynorketamines (HNKs) exert antidepressant-relevant behavioral actions and may also have analgesic, anti-inflammatory, and other physiological effects that are relevant for the treatment of a variety of human diseases. Expand
The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder.
Because of limited evidence for efficacy and risk for misuse and diversion, the use of oral and other formulations of racemic ketamine should be limited to specialists with ketamine-prescribing expertise and affiliations with tertiary or specialized centers. Expand
Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression
Results replicate those of a recently published study documenting a relationship between higher ( 2S,6S;2R,6R )-HNK concentrations and weaker antidepressant response in humans and provide further rationale for studying gamma power changes as potential biomarkers of antidepressant response. Expand
Ketamine pharmacokinetics in recipients and donors of ABO blood type-compatible and -incompatible living kidney transplantation
It is concluded that ketamine can be safely applied as an adjuvant with intravenous anesthesia during ABO blood type-compatible and -incompatible living kidney transplantation. Expand
Preclinical toxicological study of prolonged exposure to ketamine as an antidepressant.
Toxicological tests of prolonged treatment using three different doses of ketamine in adult male rats indicate that ketamine is a promising drug for repurposing as an antidepressant, and alterations observed are minor and due to a predicted mechanism of action. Expand
Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Pharmacological target deconvolution of ketamine and its metabolites will provide insight critical to the development of new pharmacotherapies that possess the desirable clinical effects of ketamines, but limit undesirable side effects. Expand